These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27888673)

  • 1. Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy.
    Carvalho FR; Cosendey RI; Souza CF; Medeiros T; Menezes PA; Silva AA; Almeida JR; Lugon JR
    Braz J Infect Dis; 2017; 21(1):51-56. PubMed ID: 27888673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients.
    Kusne S; Grossi P; Irish W; St George K; Rinaldo C; Rakela J; Fung J
    Transplantation; 1999 Oct; 68(8):1125-31. PubMed ID: 10551640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
    Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
    J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
    Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
    Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.
    Villa M; Lage E; Ballesteros S; Cañas E; Sánchez M; Ordóñez A; Borrego JM; Hinojosa R; Cisneros JM
    Transplant Proc; 2003 Mar; 35(2):732-4. PubMed ID: 12644115
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
    Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
    Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
    Nichols WG; Corey L; Gooley T; Drew WL; Miner R; Huang M; Davis C; Boeckh M
    Blood; 2001 Feb; 97(4):867-74. PubMed ID: 11159510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus (CMV) DNA amplification from plasma compared with CMV pp65 antigen (ppUL83) detection in leukocytes for early diagnosis of symptomatic CMV infection in kidney transplant patients.
    Wirgart BZ; Claesson K; Eriksson BM; Brundin M; Tufveson G; Tötterman T; Grillner L
    Clin Diagn Virol; 1996 Nov; 7(2):99-110. PubMed ID: 9137866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of preemptive therapy using a very low threshold of pp65 antigenemia to prevent cytomegalovirus disease in kidney transplant recipients: a single-center experience.
    Saracino A; Colucci R; Latorraca A; Muscaridola N; Procida C; Di Noia I; Santospirito VE; Santarsia G
    Transplant Proc; 2013; 45(1):182-4. PubMed ID: 23375295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of pp65 antigenemia and viremia in the follow-up of renal transplant recipients with cytomegalovirus disease treated with ganciclovir.
    Reina J; Ballesteros F; Gasco J; Munar M; Mari M
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):83-6. PubMed ID: 10863101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of human Cytomegalovirus infection by antigenemia and viremia in the first 100 days following renal transplantation and relation to antiviral strategies.
    Terlizzi ME; Costa C; Astegiano S; Sidoti F; Vendrame R; Segoloni GP; Bergallo M; Cavallo R
    Minerva Med; 2008 Jun; 99(3):231-9. PubMed ID: 18497721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.